Valutazione del rischio cardiometabolico nei pazienti affetti da malattie reumatiche autoimmuni

Title

Code

BC2AD

Type

Osservazionale

Start Year

2020

Status

Terminato

Principal Investigator

051-6366386

francesco.ursini@ior.it

Prof. Ursini Francesco

Medicine and Rheumatology

Operational unit that carry out the study

departmental simple unit

Medicina e reumatologia

Temporary Head

Faldini Cesare, MD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. BC2AD

Wednesday 14 September 2022, 17:23

PG0016374_2020_BC2AD.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

Valutazione del rischio cardiometabolico nei pazienti affetti da malattie reumatiche autoimmuni

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

Valutazione del rischio cardiometabolico nei pazienti affetti da malattie reumatiche autoimmuni

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in